Abstract: The invention relates to methods for fabricating a flowable hemostatic composition. The invention also relates to hemostatic compositions and methods for promoting wound healing. In various embodiments, the hemostatic compositions comprise crosslinkable collagen molecules having a porosity controlled by the ratio of weight percent collagen solids to weight percent crosslinker when crosslinking the collagen. In other embodiments, the hemostatic compositions comprise crosslinkable collagen molecules having a porosity controlled by the temperature and rate of freezing when drying the composition during fabrication. In some embodiments, the compositions contain additional agents, including biological agents.
Type:
Grant
Filed:
August 5, 2016
Date of Patent:
July 4, 2017
Assignee:
Orthovita, Inc.
Inventors:
Marissa M. Conrad, Lauren S. Valdes, Jenny E. Morgan, Alice Bachert, Abigail Cohen
Abstract: The invention relates to systems and therapeutic methods to reduce plaque causing Peyronie's disease. One approach uses high pressure injection of collagenase-containing composition into a penile plaque. Plaque disruption is enhanced by the mechanical force of the high pressure, followed by the enzymatic action of collagenase. Another approach uses collagenase as a pretreatment, followed by addition of adipose-derived stem cells ADSCs. The initial collagenase injection breaks down collagen (often more type III than type I in Peyronie's) to provide short term benefit. The longer-term benefit is provided by introduction of ADSCs to the plaque, which can produce cytokines and other signals for revascularization, and restoration of normal penile tissue. The resulting combination advantageously reduces the bulk of the plaque early on with ongoing reduction through the revascularization of the tissue. In addition, the treatment provides an advantageous shift of elastin and collagen ratios.
Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.
Type:
Grant
Filed:
June 4, 2014
Date of Patent:
June 13, 2017
Assignee:
REBIOTIX, INC.
Inventors:
Lee A. Jones, Courtney R. Jones, Edwin J. Hlavka, Ryan D. Gordon
Abstract: Extracorporeal blood treatment is performed daily on a large number of patients by use of for example a dialysis filter, plasma filter or a centrifuge. The purpose of the treatment is to separate minor components and molecules in a liquid or in the blood from larger ones, for example in connection with different disease conditions or with a view to extracting blood plasma, target substances such as blood components or molecules from for example blood donors. According to the present invention two separation steps are used together with a solution or a suspension containing at least one component, which specifically may bind to the component or the blood component to be specifically reduced, or to be refined/extracted during the treatment or during the blood treatment.
Abstract: The present invention relates to methods for recellurization of blood vessels. This method is particularly useful for producing an allogeneic vein, wherein a donor vein is decellularized and then recellularized using whole blood or bone marrow stem cells. The allogeneic veins produced by the methods disclosed herein are particularly advantageous for implantation or transplantation into patients with vascular diseases.
Type:
Grant
Filed:
June 1, 2016
Date of Patent:
May 30, 2017
Assignee:
NOV AHEP AB
Inventors:
Suchitra Sumitran-Holgersson, Michael Olausson
Abstract: A composting system for promoting aerobic microbial activity in a composting bed. The system includes at least one composting bay for receiving composting material and an agitator for aerating and displacing composting material as it travels through the composting bay. Compost produced by the system is used in place of traditional woody amendment material for mixing with incoming material to be composted.
Abstract: Methods and systems for automatically identifying and enumerating early granulated cells (EGC) in blood samples are disclosed. In one embodiment a method for identifying EGC in a blood sample includes analyzing white blood cells of the blood sample using a low angle light scatter (LALS) parameter, separating the EGCs from the other white blood cells using the LALS parameter, and enumerating the separated EGCs.
Abstract: The invention relates to systems and methods for production of compounds by yeast and other organisms. In one approach yeast engineered for production of a compound of commercial value is cultured together with a cellulosic bacteria, and the yeast uses a metabolic product produced by the bacteria as a carbon source. Methyl halides are an example of compounds that may be produced by this process. The invention also relates to production of organic compounds using genetically engineered organisms expressing a S-adenosylmethionine (SAM)-dependent methyl halide transferase. In one approach the organism, halides and a carbon source are incubated in a cultivation medium under conditions in which methyl halide is produced. The methyl halide may be collected and converted into non-halogenated organic molecules.
Type:
Grant
Filed:
November 26, 2008
Date of Patent:
May 23, 2017
Assignee:
The Regents of the University of California
Abstract: In one aspect, films that can serve as a model or mimic for the basal lamina are described herein. In some embodiments, a film described herein comprises a top surface and a bottom surface in facing opposition to the top surface, wherein the film is formed from Type I collagen and one or more additional extracellular matrix proteins. The additional extracellular matrix proteins, in some cases, comprise one or more of Type IV collagen, laminin, and fibronectin. Moreover, in some instances, the weight ratio of Type I collagen to the additional extracellular matrix proteins in the film is at least about 40:1.
Type:
Grant
Filed:
July 12, 2013
Date of Patent:
May 9, 2017
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Young-Tae Kim, Sreevidhya Banda, Deepika Tamuly
Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.
Type:
Grant
Filed:
November 12, 2015
Date of Patent:
May 9, 2017
Assignee:
REBIOTIX, INC.
Inventors:
Lee A. Jones, Courtney R. Jones, Edwin J. Hlavka, Ryan D. Gordon
Abstract: Disclosed herein are methods for cryopreserving cells and tissues under clinical conditions, allowing production of viable cell products suitable for transplantation.
Type:
Grant
Filed:
February 3, 2014
Date of Patent:
April 25, 2017
Assignee:
PrimeGen Biotech LLC
Inventors:
Fariborz Izadyar, Jason Pacchiarotti, Marnie Olmstead, Kyle Howerton, Thomas Ramos
Abstract: Described is the use of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria as a medicament, in particular, for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus, as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g., obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes) in a subject in need thereof, the method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.
Abstract: It is an object of the present invention to provide a cell three-dimensional construct that has a thickness sufficient for tissue regeneration and comprises cells uniformly distributed therein. The present invention provides a cell construct comprising polymer blocks having biocompatibility and cells, wherein the plural polymer blocks are arranged in spaces between the plural cells.
Abstract: The present invention provides methods to promote the proliferation of undifferentiated pluripotent stem cells in defined media. Specifically, the invention provides a defined cell culture formulation for the culture, maintenance, and expansion of pluripotent stem cells, wherein culturing stem cells in the defined cell culture formulation maintains the pluripotency and karyotypic stability of the cells for at least 10 passages. Further disclosed is a cell population, grown under defined media conditions, that expresses OCT4, SOX2, NANOG, and FOXA2.
Abstract: Method of in vitro measurement of the presence of factors that are able to neutralize asparaginase activity in a sample of blood, plasma, serum or derived medium that may contain asparaginase neutralizing factors, obtained from a patient, comprising mixing of said sample with asparaginase, incubation of said mixture, then measurement of the residual asparaginase activity in the mixture and determination or quantification of the presence of said neutralizing factors. Method for predicting the efficacy of a treatment with asparaginase.
Abstract: The present invention relates to producing micropropagules from Trichoderma citrinoviride EGE-K-130 mold strain isolated from resources of our country and whose strain is molecularly identified, as a bio-control agent by means of an economical production process.
Type:
Grant
Filed:
December 26, 2013
Date of Patent:
January 24, 2017
Assignee:
T.C. EGE UNIVERSITESI
Inventors:
Rengin Eltem, Sargin Sayit, Secil Sozer, Fazilet Vardar Sukan
Abstract: A method for enhancing the therapeutic effect of a stem cell is provided. The method comprises treating the stem cell with ligustilide, wherein the treatment is conducted in a culture medium of the stem cell. A method of stem cell treatment is also provided, comprising administering to a subject in need an effective amount of a stem cell or a combination of ligustilide and a stem cell, wherein the stem cell has been treated with ligustilide.
Type:
Grant
Filed:
November 24, 2014
Date of Patent:
January 3, 2017
Assignee:
GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD.
Abstract: A method for enhancing the therapeutic effect of a stem cell on autoimmune diseases, cardiovascular diseases, and/or hematological diseases is provided. The method comprises treating the stem cell with ligustilide, wherein the treatment is conducted in a culture medium of the stem cell. A method of stem cell treatment is also provided, comprising administering to a subject suffering from autoimmune diseases, cardiovascular diseases, and/or hematological diseases an effective amount of a stem cell or a combination of ligustilide and a stem cell, wherein the stem cell has been treated with ligustilide.
Type:
Grant
Filed:
August 7, 2015
Date of Patent:
December 20, 2016
Assignee:
GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD.